Cholesterol lowering with inclisiran: a new chapter in the PCSK9 story book
- PMID: 36331316
- DOI: 10.1093/eurheartj/ehac656
Cholesterol lowering with inclisiran: a new chapter in the PCSK9 story book
Conflict of interest statement
Conflict of interest: R.D.S. has received honoraria related to consulting, research, and/or speaker activities from: Abbott, Aché, Amgen, Amryt, Astra Zeneca, Biolab, Esperion, Eli-Lilly, EMS, Getz Pharma, Kowa, Libbs, Novo-Nordisk, Novartis, Merck, Pfizer, PTC, and Sanofi. V.Z.R. has received honoraria from Aché, Amgen, Amryt, Astra Zeneca, Biolab, Daiichi-Sankyo, GSK, Libbs, Novartis, Novo Nordisk, and Sanofi.
Comment on
-
Inclisiran and cardiovascular events: a patient-level analysis of phase III trials.Eur Heart J. 2023 Jan 7;44(2):129-138. doi: 10.1093/eurheartj/ehac594. Eur Heart J. 2023. PMID: 36331326 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous